Evidence for cognitive impairment in mastocytosis: Prevalence, features and correlations to depression

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Moura, Daniela Silva ^a,b   Sultan, Serge ^e,f   Georgin Lavialle, Sophie ^a,c   Barete, Stéphane ^a,d   Lortholary, Olivier ^a,b   Gaillard, Raphael ^b,g   Hermine, Olivier ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF MONTREAL   (Canada)

^g INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; PSYCHOTROPIC AGENT;

ADULT; AGED; ARTICLE; ATTENTION DISTURBANCE; AUDITORY MEMORY; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTOCYTOSIS; MEMORY DISORDER; NEUROPSYCHOLOGICAL TEST; PREVALENCE; SCORING SYSTEM; SHORT TERM MEMORY; SYMPTOM; VISUAL MEMORY; WECHSLER MEMORY SCALE; WORKING MEMORY;

ADULT; AGED; COGNITION DISORDERS; DEPRESSION; HUMANS; MASTOCYTOSIS; MEMORY; MIDDLE AGED; PREVALENCE; YOUNG ADULT;

EID: 84862683302     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039468     Document Type: Article

References (52)

1. Lennert K, Parwaresch MR, (1979) Mast cells and mast cell neoplasia: a review. Histopathology 3: 349-365.
2. Metcalfe DD, (1991) Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 96: 2S-4S.
3. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, et al. (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25: 603-625.
4. Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD, (2003) Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am 17: 1227-1241.
5. Lanternier F, Cohen-Akenine A, Palmerini F, Feger F, Yang Y, et al. (2008) Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS One 3: e1906.
6. Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, et al. (2008) Case-control cohort study of patients' perceptions of disability in mastocytosis. PLoS One 3: e2266.
7. Rogers MP, Bloomingdale K, Murawski BJ, Soter NA, Reich P, et al. (1986) Mixed organic brain syndrome as a manifestation of systemic mastocytosis. Psychosom Med 48: 437-447.
8. Moura DS, Sultan S, Georgin-Lavialle S, Pillet N, Montestruc F, et al. (2011) Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. PLoS One 6: e26375.
9. Monastero R MF, Camarda C, Ercolani S, Camarda R, (2009) A systematic review of neuropsychiatric symptoms in mild cognitive impairment. Journal of Alzheimer's disease 18: 11-30.
10. Fossati P HP, Le Bastard G, Ergis AM, Jouvent R, Allilaire JF, (2004) Verbal memory performance of patients with a first depressive episode and patients with unipolar and bipolar recurrent depression. Journal of psychiatric research 38: 137-144.
11. Godard J GS, Baruch P, Lafleur MF, (2011) Psychosocial and neurocognitive profiles in depressed patients with major depressive disorder and bipolar disorder. Psychiatry Research jul.
12. McClintock SM HM, Greer TL, Cullum CM, (2010) Association between depression severity and neurocognitive function in major depressive disorder: a review and synthesis. Neuropsychology 24: 9-34.
13. Castaneda AE T-HA, Marttunen M, Suvisaari J, Lönnqvist J, (2008) A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults. journal of Affective disorders 106: 1-27.
14. Kohler CA, da Silva WC, Benetti F, Bonini JS, (2011) Histaminergic mechanisms for modulation of memory systems. Neural Plast 2011: 328602.
15. Larrabee GJ CTr, (1994) Estimated prevalence of age-associated memory impairment derived from standardized tests of memory function. International psychogeriatrics 6: 95-104.
16. DeCarli C, (2003) Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. The Lancet Neurology 2: 15-21.
17. Rodriguez-Sanchez E, Mora-Simon S, Patino-Alonso MC, Garcia-Garcia R, Escribano-Hernandez A, et al. (2011) Prevalence of cognitive impairment in individuals aged over 65 in an urban area: DERIVA study. BMC Neurol 11: 147.
18. Creavin ST, Gallacher J, Bayer A, Fish M, Ebrahim S, et al. (2011) Metabolic Syndrome, Diabetes, Poor Cognition, and Dementia in the Caerphilly Prospective Study. J Alzheimers Dis.
19. Peltz CB, Corrada MM, Berlau DJ, Kawas CH, (2012) Cognitive impairment in nondemented oldest-old: prevalence and relationship to cardiovascular risk factors. Alzheimers Dement 8: 87-94.
20. Yaffe K, Middleton LE, Lui LY, Spira AP, Stone K, et al. (2011) Mild cognitive impairment, dementia, and their subtypes in oldest old women. Arch Neurol 68: 631-636.
21. Caceres F, Vanotti S, Rao S, Workgroup R (2011) Epidemiological characteristics of cognitive impairment of multiple sclerosis patients in a Latin American country. J Clin Exp Neuropsychol 33: 1094-1098.
22. Bobholz JA, Rao SM, (2003) Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 16: 283-288.
23. Rao SM, Leo GJ, Bernardin L, Unverzagt F, (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41: 685-691.
24. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, et al. (2009) Inflammation Causes Mood Changes Through Alterations in Subgenual Cingulate Activity and Mesolimbic Connectivity. Biological Psychiatry 66: 407-414.
25. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, et al. (2010) A Meta-Analysis of Cytokines in Major Depression Biological Psychiatry 67: 446-457.
26. Haroon E, Raison CL, Miller AH, (2012) Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37: 137-162.
27. Buckner RL, (2003) Functional-anatomic correlates of control processes in memory. The journal of neuroscience 15: 3999-4004.
28. Silverman A-J, Asarian L, Khalil M, Silver R, Ishwar SP, (2002) GnRH, brain mast cells and behavior. Progress in Brain Research: Elsevier. pp 315-325.
29. Silverman AJ, Millar RP, King JA, Zhuang X, Silver R, (1994) Mast cells with gonadotropin-releasing hormone-like immunoreactivity in the brain of doves. Proc Natl Acad Sci U S A 91: 3695-3699.
30. Wilhelm M, (2010) Neuro-immune interactions in the dove brain. General and Comparative Endocrinology 172: 173-180.
31. Lescheid DW, Terasawa E, Abler LA, Urbanski HF, Warby CM,et al. (1997) A second form of gonadotropin-releasing hormone (GnRH) with characteristics of chicken GnRH-II is present in the primate brain. Endocrinology 138: 5618-5629.
32. Craig MC, Brammer M, Maki PM, Fletcher PC, Daly EM, et al. (2010) The interactive effect of acute ovarian suppression and the cholinergic system on visuospatial working memory in young women. Psychoneuroendocrinology 35: 987-1000.
33. Pang X, Letourneau R, Rozniecki JJ, Wang L, Theoharides TC, (1996) Definitive characterization of rat hypothalamic mast cells. Neuroscience 73: 889-902.
34. Phan KL, Wager T, Taylor SF, Liberzon I, (2002) Functional Neuroanatomy of Emotion: A Meta-Analysis of Emotion Activation Studies in PET and fMRI. NeuroImage 16: 331-348.
35. Mair RG, Hembrook JR, (2008) Memory enhancement with event-related stimulation of the rostral intralaminar thalamic nuclei. J Neurosci 28: 14293-14300.
36. Nautiyal KM, Ribeiro AC, Pfaff DW, Silver R, (2008) Brain mast cells link the immune system to anxiety-like behavior. Proc Natl Acad Sci U S A 105: 18053-18057.
37. Theoharides TC, Doyle R, (2008) Autism, gut-blood-brain barrier, and mast cells. J Clin Psychopharmacol 28: 479-483.
38. Theoharides TC, Angelidou A, Alysandratos KD, Zhang B, Asadi S, et al. (2012) Mast cell activation and autism. Jan;1822(1):34-41 Epub 2010 Dec 28.
39. Theoharides T, (2009) Autism spectrum disorders and mastocytosis. Int J Immunopathol Pharmaco 22: 859-865.
40. Matsumoto I, Inoue Y, Shimada T, Aikawa T, (2001) Brain mast cells act as an immune gate to the hypothalamic-pituitary-adrenal axis in dogs. J Exp Med 194: 71-78.
41. Esposito P, Gheorghe D, Kandere K, Pang X, Connolly R, et al. (2001) Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res 888: 117-127.
42. Theoharides TC, Spanos C, Pang X, Alferes L, Ligris K, et al. (1995) Stress-induced intracranial mast cell degranulation: a corticotropin-releasing hormone-mediated effect. Endocrinology 136: 5745-5750.
43. Theoharides TC, Singh KL, Boucher W, Pang X, Letourneau R, et al. (1998) Corticotropin-Releasing Hormone Induces Skin Mast Cell Degranulation and Increased Vascular Permeability, A Possible Explanation for Its Proinflammatory Effects. Endocrinology 139: 403-413.
44. Heesen C, Gold SM, Raji A, Wiedemann K, Schulz KH, (2002) Cognitive impairment correlates with hypothalamo-pituitary-adrenal axis dysregulation in multiple sclerosis. Psychoneuroendocrinology 27: 505-517.
45. Carroll JC, Iba M, Bangasser DA, Valentino RJ, James MJ, et al. (2011) Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy. J Neurosci 31: 14436-14449.
46. Bruehl H, Rueger M, Dziobek I, Sweat V, Tirsi A, et al. (2007) Hypothalamic-pituitary-adrenal axis dysregulation and memory impairments in type 2 diabetes. J Clin Endocrinol Metab 92: 2439-2445.
47. Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, et al. (2011) Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther 3: 16.
48. Paul C, Sans B, Suarez F, Casassus P, Barete S,et al. (2010) Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 85: 921-925.
49. Plangar I, Zadori D, Klivenyi P, Toldi J, Vecsei L, (2011) Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy. J Alzheimers Dis 24: 199-209.
50. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, et al. (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145: 863-874.
51. Wechsler D, (1987) Wechsler Memory Scale,Revised. The Psychological Corporation San Antonio, TX.
52. Hamilton M, (1960) A rating scale for depression J Neurol Neurosurg Psychiatry 23: 56-62.